GMED - Globus Medical, Inc. Последние новости | Finranks

11.08.2026

Globus Medical (GMED) Upgraded to Strong Buy: Here's Why

Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11.08.2026

GMED vs. ITGR: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors?

08.08.2026

Globus Medical Q2 Earnings Call Highlights

Globus Medical NYSE: GMED reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half.

07.08.2026

GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution

Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.

07.08.2026

Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

07.08.2026

Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript

07.08.2026

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Globus Medical (GMED) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.86 per share a year ago.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
GMED	UBS	Neutral	undefined >> $82	July 28th 2026

Пресс-релизы

06.08.2026

Globus Medical Reports Second Quarter 2026 Results

AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026.

Globus Medical, Inc. (GMED)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Globus Medical, Inc. (GMED)

Globus Medical (GMED) Upgraded to Strong Buy: Here's Why

GMED vs. ITGR: Which Stock Is the Better Value Option?

Globus Medical Q2 Earnings Call Highlights

GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution

Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Globus Medical Reports Second Quarter 2026 Results

Search stocks

Globus Medical, Inc. (GMED)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Globus Medical, Inc. (GMED)

Globus Medical (GMED) Upgraded to Strong Buy: Here's Why

GMED vs. ITGR: Which Stock Is the Better Value Option?

Globus Medical Q2 Earnings Call Highlights

GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution

Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Globus Medical Reports Second Quarter 2026 Results